医学
肝细胞癌
生物标志物
液体活检
阶段(地层学)
肿瘤科
活检
内科学
肝活检
癌
癌症
重症监护医学
古生物学
生物化学
化学
生物
作者
Lauren Tal Grinspan,Augusto Villanueva
出处
期刊:Seminars in Liver Disease
[Georg Thieme Verlag KG]
日期:2022-05-01
卷期号:42 (02): 188-201
被引量:6
标识
DOI:10.1055/s-0042-1748924
摘要
Liver cancer incidence rate continues to increase and currently ranks third in the total number of annual deaths, behind only lung and colorectal cancer. Most patients with hepatocellular carcinoma (HCC) are diagnosed at advanced stages, and they live for less than 2 years after diagnosis on average. This contrasts with those diagnosed at an early stage, who can be cured with surgery. However, even after curative resection, there remains a risk of up to 70% of postoperative HCC recurrence. There have been major changes in the management of HCC in the past 5 years, particularly for patients at advanced stages. Despite this multitude of new therapies, there is a lack of clear biomarkers to guide providers on the best approach to sequence therapies, which would maximize efficacy while minimizing toxicity. There are several areas in clinical management of HCC that are particularly challenging, and would benefit from development and implementation of new biomarkers to improve patient overall survival. Here, we review the major advances in liquid biopsy biomarkers for early detection of HCC, minimum residual disease, and predicting response to treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI